SCH772984 is a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors. SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRAS, or KRAS. SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. SCH772984 induces tumor regressions in xenograft models at tolerated doses.
Phytomedicine. 2022 Jun;100:154068.
Geniposide alleviates VEGF-induced angiogenesis by inhibiting VEGFR2/PKC/ERK1/2-mediated SphK1 translocation
SCH772984 purchased from AbMole
Mol Cancer. 2022 Mar 18;21(1):77.
Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression
SCH772984 purchased from AbMole
Cancer Immunol Res. 2020 Oct;8(10):1273-1286.
An IL6-Adenosine Positive Feedback Loop between CD73 + γδTregs and CAFs Promotes Tumor Progression in Human Breast Cancer
SCH772984 purchased from AbMole
Onco Targets Ther. 2020 Jul 31;13:7585-7598.
JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells
SCH772984 purchased from AbMole
Acta Pharmacol Sin. 2019 Dec 17.
Acid sphingomyelinase downregulation alleviates vascular endothelial leptin resistance in rats.
SCH772984 purchased from AbMole
Cell. 2019 Mar 7;176(6):1379-1392.e14.
Lateral Inhibition in Cell Specification Mediated by Mechanical Signals Modulating TAZ Activity.
SCH772984 purchased from AbMole
J Neurosci 2018 Mar 26.
HIPK2-mediated transcriptional control of NMDA receptor subunit expression regulates neuronal survival and cell death
SCH772984 purchased from AbMole
Saudi Pharmaceutical Journal. 2016 May;24(3):354-62.
Analgesic effect and possible mechanism of SCH772984 intrathecal injection on rats with bone cancer pain.
SCH772984 purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | BRAF- or RAS-mutant tumor cells |
Preparation method | Cell proliferation experiments were carried out in a 96-well format (six replicates), and cells were plated at a density of 4,000 cells per well. At 24 hours after cell seeding, cells were treated with DMSO or a 9-point IC50 dilution (0.001–10 μmol/L) at a final concentration of 1% DMSO for all concentrations. Viability was assayed 5 days after dosing using the ViaLight luminescence kit (Lonza) following the manufacturer's recommendations (n = 6, mean ± SE). For the cell line panel viability assay, cells were treated with SCH772984 for 4 days and assayed by the CellTiterGlo luminescent cell viability assay (Promega). |
Concentrations | 0.001–10 μmol/L |
Incubation time | 4 days |
Animal Experiment | |
---|---|
Animal models | Female nude mice bearing human LOX BRAF-mutant/MiaPaCa KRAS-mutant pancreatic/ melanoma xenograft model |
Formulation | normal saline |
Dosages | 12.5, 25, or 50 mg/kg for 14 days |
Administration | intraperitoneally |
Molecular Weight | 587.67 |
Formula | C33H33N9O2 |
CAS Number | 942183-80-4 |
Solubility (25°C) | DMSO 12 mg/mL warming |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related ERK Products |
---|
RLX-33
RLX-33 is a potent and selective blood-brain barrier permeable relaxin family peptide 3 (RXFP3) antagonist that also blocks relaxin 3 (Relaxin 3) -induced ERK1/2 phosphorylation. The IC50 phosphorylated RXFP3, ERK1 and ERK2 were 2.36μM, 7.82μM and 13.86μM, respectively. RLX-33 can block the increase of food intake in rats induced by RXFP3 selective agonist R3/I5. RLX-33 can be used in the study of metabolic syndrome. |
XMD8-85 (ERK5-IN-1)
XMD8-85 (ERK5-IN-1) is a selective and potent inhibitor of ERK5 and LRRK2 with IC50s of 0.162 μM and 0.339 μM, respectively. |
WAY-340245
WAY-340245 is a ERK inhibitor. |
Ulixertinib hydrochloride
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. |
Magnolin
Magnolin, a major component of Magnolia flos (Shin-Yi), inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of ERK1 and ERK2 with IC50s of 87 nM and 16.5 nM, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.